Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

Muhammad Zaeem Noman, Santiago Parpal, Kris Van Moer, Malina Xiao, Yasmin Yu, Tsolère Arakelian, Jenny Viklund, Angelo De Milito, Meriem Hasmim, Martin Andersson,

Science Advances · 2020 · 251 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

T effector cells in melanoma and CRC tumors. Such infiltration resulted in the establishment of a T cell-inflamed tumor microenvironment, characterized by the up-regulation of pro-inflammatory chemokines and cytokines, CCL5, CXCL10, and IFNγ. Vps34i treatment induced STAT1 and IRF7, involved in the up-regulation of CCL5 and CXCL10. Combining Vps34i improved the therapeutic benefit of anti-PD-L1/PD-1 in melanoma and CRC and prolonged mice survival. Our study revealed that targeting Vps34 turns cold into hot inflamed tumors, thus enhancing the efficacy of anti-PD-L1/PD-1 blockade.

References

28